Inculet R I, Stein T P, Peacock J L, Leskiw M, Maher M, Gorschboth C M, Norton J A
Cancer Res. 1987 Sep 1;47(17):4746-9.
Leucine and whole body protein metabolism were quantitated in 26 human subjects (6 sarcoma patients, 20 age-matched normal controls) using a primed, continuous infusion of [13C]leucine. Plasma samples were analyzed every 15 min for enrichment of [13C]leucine. Plateau enrichment levels were then used to calculate whole-body protein turnover, synthesis, and breakdown rates. Exhaled gas samples were analyzed every 15 min for enrichment of 13CO2, and plateau enrichment levels (as well as CO2 production rates) were used to calculate leucine oxidation rates. Fasting plasma amino acid levels, serum albumin, and total protein levels were also determined. The 6 patients were otherwise healthy but had a large, localized high-grade sarcoma which had not been previously treated. No patient had weight loss. Amino acid, albumin, and total protein levels were equivalent in patients and controls. Whole-body protein turnover rates were significantly greater in sarcoma patients than age-matched controls (15%). Increased protein turnover rates resulted in increased whole-body protein synthesis and breakdown rates in sarcoma patients compared to controls. Leucine oxidation rates were not different in the 2 groups. The results suggest that in humans with high-grade sarcomas leucine metabolic abnormalities are specific to tumor growth and not malnutrition because abnormalities of turnover, synthesis, and breakdown occur prior to any weight loss or measurable change in blood amino acid or protein level.
使用[13C]亮氨酸的预充式连续输注,对26名人类受试者(6名肉瘤患者,20名年龄匹配的正常对照)的亮氨酸和全身蛋白质代谢进行了定量分析。每15分钟分析一次血浆样本中[13C]亮氨酸的富集情况。然后使用平台期富集水平来计算全身蛋白质周转率、合成率和分解率。每15分钟分析一次呼出气体样本中13CO2的富集情况,并使用平台期富集水平(以及CO2产生率)来计算亮氨酸氧化率。还测定了空腹血浆氨基酸水平、血清白蛋白和总蛋白水平。这6名患者在其他方面健康,但患有一个大的、局部的高级别肉瘤,此前未接受过治疗。没有患者体重减轻。患者和对照组的氨基酸、白蛋白和总蛋白水平相当。肉瘤患者的全身蛋白质周转率显著高于年龄匹配的对照组(15%)。与对照组相比,肉瘤患者蛋白质周转率的增加导致全身蛋白质合成和分解率增加。两组的亮氨酸氧化率没有差异。结果表明,在患有高级别肉瘤的人类中,亮氨酸代谢异常是肿瘤生长特有的,而非营养不良,因为周转率、合成和分解的异常发生在任何体重减轻或血液氨基酸或蛋白质水平出现可测量变化之前。